Followers | 0 |
Posts | 1298 |
Boards Moderated | 0 |
Alias Born | 03/30/2020 |
Monday, May 18, 2020 4:56:28 PM
Recent AIM News
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 07/03/2024 12:55:00 PM
- AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference • GlobeNewswire Inc. • 06/10/2024 12:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 02:15:24 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/03/2024 02:05:35 PM
- AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series • GlobeNewswire Inc. • 06/03/2024 01:15:00 PM
- AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering • GlobeNewswire Inc. • 05/31/2024 12:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/31/2024 12:14:18 PM
- AIM ImmunoTech to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/20/2024 01:15:00 PM
- AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/16/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:31:34 PM
- AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast • GlobeNewswire Inc. • 05/09/2024 12:50:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 12:30:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 12:30:31 PM
- AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® • GlobeNewswire Inc. • 05/06/2024 12:30:00 PM
- AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer • GlobeNewswire Inc. • 04/29/2024 12:55:00 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 04/25/2024 12:45:00 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 04/18/2024 12:45:00 PM
- AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs • GlobeNewswire Inc. • 04/15/2024 12:55:00 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 04/11/2024 03:00:00 PM
- AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer • GlobeNewswire Inc. • 04/10/2024 12:21:00 PM
- AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/02/2024 11:30:00 AM
- AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference • GlobeNewswire Inc. • 03/28/2024 12:05:00 PM
- AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast • GlobeNewswire Inc. • 03/26/2024 01:05:00 PM
- AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research • GlobeNewswire Inc. • 03/25/2024 01:05:00 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 03/22/2024 12:55:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM